All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @modern_dreamer on TikTok · 37s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @modern_dreamer's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00The same one of my pepper journeys just got my peps going with ratatouille.
  2. 0:04That's the one that just seems to do better long term.
  3. 0:07A lot of people who start on tea don't like moving over to ratatouille.
  4. 0:11Don't like it when they move that direction so I rather start the opposite direction.
  5. 0:15I am starting at 0.5 milligrams.
  6. 0:17Again, I am researching y'all. This is all research.
  7. 0:19I'm splitting it into two doses twice a week.
  8. 0:22Typically, I am super sleepy no matter what I take.
  9. 0:25I do have nausea issues.
  10. 0:26So definitely doing a split dose.
  11. 0:28My weekly dose is 0.5 for the week.
  12. 0:30So I'm a split 0.25 and 0.25.
  13. 0:34Follow me, you guys, on my journey doing peppers.
  14. 0:36What are you doing?

@modern_dreamer's peptide therapy claims need context

Jasmine Olivia 💖

TikTok creator

49.3K viewsWatch on TikTok →

Quick answer

The creator appears to be self-administering CJC-1295 at 0.25 mg twice weekly, a below-average dose compared to published clinical protocols, citing personal tolerability concerns including nausea and hypersomnia. Neither CJC-1295 nor ipamorelin holds FDA approval for wellness or longevity indications, and compounded versions face ongoing regulatory scrutiny. Self-reported side effects like sleepiness and nausea are consistent with known GH secretagogue effects, but without lab monitoring, there is no way to assess actual GH or IGF-1 response at this dose.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @modern_dreamer's peptide therapy claims need context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@modern_dreamer's peptide therapy claims need context is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@modern_dreamer's peptide therapy claims need context" from Jasmine Olivia 💖. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator appears to be self-administering CJC-1295 at 0.

The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7585332658549361950." In this clip, the useful excerpt is: "The same one of my pepper journeys just got my peps going with ratatouille." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Neither CJC-1295 nor ipamorelin is FDA-approved for anti-aging, recovery, or wellness purposes.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator appears to be self-administering CJC-1295 at 0.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator appears to be self-administering CJC-1295 at 0.25 mg twice weekly, a below-average dose compared to published clinical protocols, citing personal tolerability concerns including nausea and hypersomnia. Neither CJC-1295 nor ipamorelin holds FDA approval for wellness or longevity indications, and compounded versions face ongoing regulatory scrutiny. Self-reported side effects like sleepiness and nausea are consistent with known GH secretagogue effects, but without lab monitoring, there is no way to assess actual GH or IGF-1 response at this dose.
  • CJC-1295 was studied in humans by Jetté et al. (2006) at doses far above 0.5 mg total weekly, with GH elevation lasting days after a single injection. The creator's dose is below published clinical ranges.
  • Neither CJC-1295 nor ipamorelin is FDA-approved for anti-aging, recovery, or wellness purposes. Both exist in a compounding gray zone that is under active regulatory scrutiny as of 2023-2024.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • CJC-1295 was studied in humans by Jetté et al. (2006) at doses far above 0.5 mg total weekly, with GH elevation lasting days after a single injection. The creator's dose is below published clinical ranges.
  • Neither CJC-1295 nor ipamorelin is FDA-approved for anti-aging, recovery, or wellness purposes. Both exist in a compounding gray zone that is under active regulatory scrutiny as of 2023-2024.
  • Splitting doses to reduce nausea and sedation is a reasonable tolerability approach, but no human trial has validated this specific protocol for CJC-1295 at 0.25 mg twice weekly.
  • The claim that CJC-1295 outperforms ipamorelin long-term has no peer-reviewed backing. It reflects community convention, not comparative clinical data.
  • Known side effects of GH secretagogues include water retention, elevated fasting glucose, and changes in cortisol and prolactin, none of which can be detected without lab monitoring.
  • Self-experimentation with injectable peptides without clinician oversight and baseline labs removes the safety net that catches early adverse signals before they become serious problems.
  • Coded language like 'ratatouille' and 'peppers' protects social media accounts but provides zero protection to viewers who may not know what compound is actually being discussed or what risks it carries.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @modern_dreamer actually say?

The creator is documenting a personal peptide experiment, apparently choosing to start with what sounds like CJC-1295 ("ratatouille" in their terminology) over ipamorelin ("tea"), citing a preference for long-term outcomes. They're dosing at 0.5 mg per week, split into two 0.25 mg subcutaneous injections, twice weekly. They mention sleepiness and nausea as expected side effects and frame everything as "research."

The coded language here, "peppers," "ratatouille," "tea," is a workaround for platform content policies. It's worth naming what's actually being discussed: these are likely growth hormone secretagogues, specifically CJC-1295 and ipamorelin, which stimulate the pituitary to release growth hormone. The creator is not claiming medical results. They're sharing a self-directed experiment. That framing matters.

Does the science back up their dosing approach?

Split dosing to manage tolerability has some logic behind it, but the specific numbers here don't map cleanly to published research. CJC-1295 has been studied in humans at doses well above 0.5 mg total weekly, and the tolerability data doesn't fully support the creator's reasoning.

A 2006 study by Jetté et al. published in the Journal of Clinical Endocrinology and Metabolism examined CJC-1295 in healthy adults at single doses ranging from 30 mcg/kg to 120 mcg/kg, finding dose-dependent GH release lasting several days. Their subjects weren't splitting doses across a week at this scale. Ipamorelin, studied by Raun et al. (1998, European Journal of Endocrinology), showed GH pulse amplification in animal models, with human data remaining limited. Combining the two is a common practice in wellness circles, but peer-reviewed data on that combination in humans is essentially nonexistent. The creator's 0.5 mg weekly total is lower than most published protocols, which isn't necessarily wrong, but calling it "research" while citing personal anecdote blurs that line considerably.

What did they get right, and what needs pushback?

Credit where it's due: splitting doses to manage nausea and sleepiness is a reasonable harm-reduction move. GH secretagogues are known to cause transient hypersomnia and GI discomfort, particularly at higher doses or in sensitive individuals. The creator isn't stacking aggressively or claiming dramatic outcomes, which puts them in better shape than most peptide content on this platform.

The problems are structural. First, the "research" framing is misleading. Personal self-experimentation is not research in any scientific sense. There's no control, no monitoring, no endpoints. Second, the preference claim, that CJC-1295 does "better long term" than ipamorelin, is stated as if it's an established fact. It isn't. Long-term human data on either compound is sparse, and no peer-reviewed trial has directly compared them over extended periods. Third, the coded language protects the creator's account, but it does nothing to protect viewers who may be less informed about what they're actually considering injecting. The cheerful "follow me on my journey" framing is particularly concerning given the regulatory and safety gaps around compounded peptides.

What should you actually know before considering these peptides?

CJC-1295 and ipamorelin are not FDA-approved for general wellness or anti-aging use. They exist in a gray zone: compounded versions circulate widely, but the FDA has flagged concerns about compounded peptides specifically. In 2023 and 2024, FDA actions targeted several peptides on the "difficult to compound" list, and the regulatory landscape for these substances is actively shifting.

Side effects beyond sleepiness and nausea include water retention, elevated fasting glucose, and potential effects on cortisol and prolactin. Long-term safety data in healthy adults is not available. Anyone considering these compounds should be doing so under the supervision of a licensed clinician who can order baseline labs, monitor IGF-1 levels, and assess cardiovascular and metabolic risk. A TikTok journey log, however well-intentioned, is not a substitute for that.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jasmine Olivia 💖 · TikTok creator

49.3K views on this video

@modern_dreamer's peptide therapy claims need context

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about cjc-1295 was studied in humans by jetté et al. (2006)?

CJC-1295 was studied in humans by Jetté et al. (2006) at doses far above 0.5 mg total weekly, with GH elevation lasting days after a single injection. The creator's dose is below published clinical ranges.

What does the video say about neither cjc-1295 nor ipamorelin?

Neither CJC-1295 nor ipamorelin is FDA-approved for anti-aging, recovery, or wellness purposes. Both exist in a compounding gray zone that is under active regulatory scrutiny as of 2023-2024.

What does the video say about splitting doses to reduce nausea?

Splitting doses to reduce nausea and sedation is a reasonable tolerability approach, but no human trial has validated this specific protocol for CJC-1295 at 0.25 mg twice weekly.

What does the video say about the claim?

The claim that CJC-1295 outperforms ipamorelin long-term has no peer-reviewed backing. It reflects community convention, not comparative clinical data.

What does the video say about known side effects of gh secretagogues include water retention, elevated?

Known side effects of GH secretagogues include water retention, elevated fasting glucose, and changes in cortisol and prolactin, none of which can be detected without lab monitoring.

What does the video say about self-experimentation with injectable peptides without clinician oversight?

Self-experimentation with injectable peptides without clinician oversight and baseline labs removes the safety net that catches early adverse signals before they become serious problems.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jasmine Olivia 💖, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.